Loading company…
Trophos develops biopharmaceutical treatments for neurodegenerative diseases, including ALS.
Founded in 1999, Trophos developed therapies for neurodegenerative diseases, with a focus on amyotrophic lateral sclerosis (ALS). The company was based in Marseille, France, and is at the Series C stage. Roche Holding agreed to acquire Trophos for EUR 470.000 mn in January 2015.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in